Compare RTO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTO | SNN |
|---|---|---|
| Founded | 1925 | 1856 |
| Country | United Kingdom | United Kingdom |
| Employees | 64084 | 16988 |
| Industry | Business Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 14.3B |
| IPO Year | N/A | N/A |
| Metric | RTO | SNN |
|---|---|---|
| Price | $29.91 | $30.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $35.00 | ★ $36.25 |
| AVG Volume (30 Days) | 862.3K | ★ 1.3M |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | 1.60% | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.05 | $8.58 |
| Revenue Next Year | $4.35 | $5.60 |
| P/E Ratio | $222.16 | ★ $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.72 | $28.56 |
| 52 Week High | $34.67 | $38.79 |
| Indicator | RTO | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 52.99 |
| Support Level | $29.27 | $29.19 |
| Resistance Level | $30.15 | $31.06 |
| Average True Range (ATR) | 0.49 | 0.55 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 64.60 | 87.42 |
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in over 90 countries, with its largest operations in the United States following the acquisition of Terminix. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.